ING Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$51M Buy
885,384
+422,731
+91% +$24.3M 0.25% 82
2026
Q1
$28.1M Buy
462,653
+137,676
+42% +$8.03M 0.17% 102
2025
Q4
$17.5M Sell
324,977
-638,156
-66% -$30.7M 0.11% 140
2025
Q3
$43.4M Buy
963,133
+669,447
+228% +$31.3M 0.24% 72
2025
Q2
$13.6M Buy
293,686
+290,075
+8,033% +$14.2M 0.08% 148
2025
Q1
$220K Sell
3,611
-463,419
-99% -$27M ﹤0.01% 474
2024
Q4
$26.4M Sell
467,030
-567,623
-55% -$31.7M 0.18% 99
2024
Q3
$53.5M Buy
1,034,653
+873,152
+541% +$41M 0.31% 57
2024
Q2
$6.71M Sell
161,501
-160,830
-50% -$7.2M 0.04% 278
2024
Q1
$17.5M Sell
322,331
-165,741
-34% -$8.44M 0.12% 150
2023
Q4
$25M Buy
488,072
+253,553
+108% +$13.3M 0.2% 101
2023
Q3
$13.6M Sell
234,519
-1,505,836
-87% -$92.3M 0.12% 158
2023
Q2
$111M Buy
1,740,355
+1,707,308
+5,166% +$114M 0.84% 20
2023
Q1
$2.29M Sell
33,047
-166,261
-83% -$11.7M 0.02% 350
2022
Q4
$14.3M Sell
199,308
-13,860
-7% -$1.05M 0.14% 124
2022
Q3
$15.2M Buy
213,168
+9,016
+4% +$654K 0.25% 84
2022
Q2
$15.7M Sell
204,152
-101,071
-33% -$7.7M 0.18% 99
2022
Q1
$22.3M Sell
305,223
-519,480
-63% -$34.9M 0.22% 81
2021
Q4
$51.4M Buy
824,703
+471,104
+133% +$27.6M 0.46% 41
2021
Q3
$20.9M Buy
353,599
+170,082
+93% +$11.2M 0.27% 64
2021
Q2
$12.3M Buy
183,517
+33,067
+22% +$2.16M 0.2% 82
2021
Q1
$9.5M Sell
150,450
-15,059
-9% -$937K 0.2% 84
2020
Q4
$10.3M Buy
165,509
+94,562
+133% +$5.81M 0.23% 73
2020
Q3
$4.28M Buy
70,947
+15,744
+29% +$948K 0.18% 80
2020
Q2
$3.25M Sell
55,203
-49,107
-47% -$2.94M 0.14% 68
2020
Q1
$5.81M Sell
104,310
-117,373
-53% -$7.17M 0.25% 63
2019
Q4
$14.2M Buy
221,683
+81,870
+59% +$4.69M 0.43% 45
2019
Q3
$7.09M Buy
139,813
+48,540
+53% +$2.28M 0.18% 98
2019
Q2
$4.14M Buy
91,273
+5,876
+7% +$274K 0.07% 177
2019
Q1
$4.07M Sell
85,397
-214,143
-71% -$10.7M 0.09% 142
2018
Q4
$15.6M Sell
299,540
-29,530
-9% -$1.59M 0.34% 58
2018
Q3
$20.4M Buy
329,070
+82,928
+34% +$4.92M 0.35% 55
2018
Q2
$13.6M Sell
246,142
-192,810
-44% -$10.4M 0.26% 62
2018
Q1
$27.8M Buy
438,952
+204,603
+87% +$13.2M 0.5% 45
2017
Q4
$14.4M Sell
234,349
-43,432
-16% -$2.72M 0.24% 57
2017
Q3
$17.7M Sell
277,781
-11,227
-4% -$656K 0.34% 60
2017
Q2
$16.1M Sell
289,008
-52,584
-15% -$2.86M 0.31% 51
2017
Q1
$18.6M Buy
341,592
+11,895
+4% +$652K 0.34% 62
2016
Q4
$19.4M Buy
329,697
+60,569
+23% +$3.31M 0.36% 56
2016
Q3
$14.5M Buy
269,128
+70,853
+36% +$4.55M 0.17% 76
2016
Q2
$14.6M Buy
198,275
+45,941
+30% +$3.25M 0.2% 63
2016
Q1
$9.73M Sell
152,334
-901,538
-86% -$56.9M 0.12% 109
2015
Q4
$72.5M Buy
1,053,872
+267,504
+34% +$17.7M 0.44% 58
2015
Q3
$46.5M Sell
786,368
-336,226
-30% -$21.3M 0.32% 72
2015
Q2
$74.7M Sell
1,122,594
-366,820
-25% -$24.2M 0.4% 56
2015
Q1
$96.1M Buy
1,489,414
+3,305
+0.2% +$207K 0.48% 45
2014
Q4
$87.7M Sell
1,486,109
-45,872
-3% -$2.59M 0.41% 56
2014
Q3
$78.4M Sell
1,531,981
-272,913
-15% -$13.6M 0.46% 48
2014
Q2
$87.5M Sell
1,804,894
-447,780
-20% -$22.1M 0.44% 46
2014
Q1
$117M Sell
2,252,674
-60,972
-3% -$3.24M 0.62% 32
2013
Q4
$123M Buy
2,313,646
+813,514
+54% +$41.4M 0.62% 33
2013
Q3
$69.4M Buy
1,500,132
+98,610
+7% +$4.33M 0.35% 69
2013
Q2
$62.6M Buy
+1,401,522
New +$60.8M 0.33% 83

Other funds holding BMY

ING Group's BMY Position: Q2 2026 in Review

ING Group increased its Bristol-Myers Squibb (BMY) stake by 91% in Q2 2026, buying an estimated $24.3M and bringing the position to 885,384 shares worth $51M. The position accounts for 0.25% of the portfolio, ranked #82.

ING Group first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $123M in Q4 2013. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • ING Group held 885,384 shares of Bristol-Myers Squibb worth $51M as of Q2 2026.
  • ING Group bought 422,731 Bristol-Myers Squibb shares in Q2 2026, an estimated $24.3M.
  • Bristol-Myers Squibb made up 0.25% of ING Group's portfolio in Q2 2026, its #82 holding.
  • ING Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • ING Group's Bristol-Myers Squibb position peaked at $123M in Q4 2013.
  • 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.